ADC Therapeutics SA EBITDA 2019-2023 | ADCT

ADC Therapeutics SA ebitda from 2019 to 2023. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
ADC Therapeutics SA Annual EBITDA
(Millions of US $)
2022 $-121
2021 $-259
2020 $-217
2019 $-118
2018 $-125
ADC Therapeutics SA Quarterly EBITDA
(Millions of US $)
2023-03-31 $-51
2022-12-31 $-10
2022-09-30 $-3
2022-06-30 $-69
2022-03-31 $-40
2021-12-31 $-62
2021-09-30 $-57
2021-06-30 $-70
2021-03-31 $-70
2020-12-31 $-77
2020-09-30 $-52
2020-06-30 $-45
2020-03-31 $-43
2019-12-31
2019-09-30 $-32
2019-06-30 $-24
2018-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.191B $0.210B
ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.942B 8.43
GSK (GSK) United Kingdom $69.839B 9.75
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.584B 22.35
Ginkgo Bioworks Holdings (DNA) United States $3.379B 0.00
Arcus Biosciences (RCUS) United States $1.536B 0.00
Biohaven (BHVN) United States $1.482B 0.00
Emergent Biosolutions (EBS) United States $0.416B 0.00
Enzo Biochem (ENZ) United States $0.110B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00